More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$563313708
EPS
-0.52
P/E ratio
--
Price to sales
--
Dividend yield
--
Beta
2.304731
Previous close
$2.02
Today's open
$1.99
Day's range
$1.87 - $2.02
52 week range
$1.86 - $5.49
show more
CEO
Steven D. Harr
Employees
142
Headquarters
Seattle, WA
Exchange
Nasdaq Global Select
Shares outstanding
299634951
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Bears are Losing Control Over Sana (SANA), Here's Why It's a 'Buy' Now
Sana (SANA) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Zacks Investment Research • Nov 16, 2026

2 healthcare stocks to turn $10 into $100 by next year
Healthcare stocks have emerged as an area of relative strength in 2026, outperforming technology shares as investors seek opportunities beyond the artificial intelligence (AI) boom.
Finbold • Nov 11, 2026

Sana Biotechnology Reports Third Quarter 2026 Financial Results and Business Updates
Continued progress toward starting SC451 Phase 1/2 trial in type 1 diabetes Continued progress toward starting clinical study for SG293 in non-Hodgkin lymphoma Announced follow-on publication in The New England Journal of Medicine (NEJM) highlighting long-term data and durability of hypoimmune-modified islet cell transplantation with UP421 without immunosuppression in type 1 diabetes Advancing strategic collaboration with Mayo Clinic, focused on improving care in type 1 diabetes and accelerating development of SC451 Continued progress with SG227, a CD8-targeted fusosome that delivers to CD8+ T cells the genetic material to make BCMA-directed CAR T cells, as a potential treatment for patients with multiple myeloma; expect to begin clinical study as early as 2027 Q3 2026 cash position of $121.7 million; expected cash runway into mid-2027 SEATTLE, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today reported financial results and business highlights for the third quarter 2026. “We continue to make meaningful progress toward initiating clinical studies of SC451 later this year and SG293 in 1Q 2027,” said Steve Harr, Sana's President and Chief Executive Officer.
GlobeNewsWire • Nov 5, 2026

Sana Biotechnology: A Shot At Diabetes
Sana Biotechnology trades at a steep discount despite promising T1D assets UP421 and SC451. UP421 demonstrated durable insulin production without immunosuppression in early data, positioning SANA as a potential T1D disruptor. Cash runway is limited to 5 quarters at the current burn, making Sana dependent on the near-term success of their pipeline.
Seeking Alpha • Oct 13, 2026

Sana Biotechnology, Inc. (SANA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Sana Biotechnology, Inc. (SANA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Seeking Alpha • Sep 15, 2026

Sana Biotechnology, Inc. (SANA) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Sana Biotechnology, Inc. (SANA) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Seeking Alpha • Sep 10, 2026

Sana Biotechnology, Inc. (SANA) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Sana Biotechnology, Inc. (SANA) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Seeking Alpha • Sep 10, 2026

Did Sana Biotechnology, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
PRNewsWire • Sep 7, 2026

Sana Biotechnology to Present at September 2026 Investor Conferences
SEATTLE, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at four investor conferences in September. The presentations will feature a business overview and update.
GlobeNewsWire • Sep 1, 2026

3 Promising Genomics Stocks to Add to Your Portfolio in 2026
Genomics is reshaping healthcare, and these three stocks - MYGN, SANA and WVE - stand out as rapid advances in personalized medicine and synthetic biology continue to transform the industry.
Zacks Investment Research • Jul 20, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Sana Biotechnology Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.